All Jerome Kim articles
-
NewsInternational Vaccine Institute, Baylor College of Medicine, and Regional Center for Innovation in Vaccines and Biopharmaceuticals AIP exchange an MOU
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, Baylor College of Medicine (Baylor), health science university and a Texas nonprofit corporation, and the Regional Center for Innovation in Vaccines and Biopharmaceuticals (CRIVB) AIP, a ...
-
NewsIVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets
The International Vaccine Institute (IVI) has announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited (BE), a leading India-based vaccines and pharmaceutical company.
-
NewsIVI to open Africa Regional Office in Rwanda
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, and the Ministry of Health of Rwanda have announced that IVI will open its Africa Regional Office in Kigali this year. The IVI ...
-
NewsSK bioscience’s typhoid conjugate vaccine achieves WHO prequalification
SK bioscience and the International Vaccine Institute (IVI) announced that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ).
-
NewsSimplified formulation of oral cholera vaccine, licensed by Korean regulatory agency
Euvichol-S, a simplified formulation of oral cholera vaccine, has been licensed by Korean regulatory agency, and is expected to alleviate global cholera vaccine shortages.
-
NewsClover’s vaccine candidate reduced household transmission of SARS-CoV-2
A collaboration between Clover Biopharmaceuticals Ltd and the International Vaccine Institute showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebos.
